Hangzhou Tigermed Consulting Co., Ltd (SZSE: 300347)
Health Care · Life Sciences Tools & Services · CN
CN¥54.37
-2.95% today · -20.8% 1Y
Hangzhou Tigermed Consulting Co., Ltd (SZSE: 300347) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $6.38B and employs 11,130 people.
Over the last twelve months the share price has lost 20.8%, trading between 35.57 and 68.87.
Tweenvest scores Hangzhou Tigermed Consulting Co., Ltd across four factors: quality 69/100, value 40/100, growth 42/100, dividend 44/100. Its strongest factor is quality.
300347 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.38B
- Revenue (TTM)
- $1.03B
- P/E
- 59.38
- EPS
- 0.92
- Dividend yield
- 0.23%
- Beta (5Y)
- 0.34
- 52-week high
- CN¥68.87
- 52-week low
- CN¥35.57
- Avg volume (3M)
- —
- Shares outstanding
- 834.18M
- Employees
- 11,130
- Next earnings
- —
About Hangzhou Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
- ISIN
- CNE100001KV8
- Founded
- 2004
- Listed since
- Aug 17, 2012
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Thermo Fisher Scientific Inc.NYSE: TMO | $232.67B | $623.96 | -0.84% |
| Danaher CorporationNYSE: DHR | $153.85B | $215.61 | -1.48% |
| WuXi AppTec Co., Ltd.SHSE: 603259 | $72.12B | CN¥162.86 | -3.00% |
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $51.75B | ₩1,551,000.00 | +0.19% |
| Lonza Group AGSWX: LONN | $51.61B | CHF587.80 | -0.74% |
| Agilent Technologies, Inc.NYSE: A | $44.91B | $152.87 | -3.86% |
| IQVIA Holdings Inc.NYSE: IQV | $42.77B | $259.37 | -0.17% |
| Waters CorporationNYSE: WAT | $40.35B | $407.60 | -0.75% |
Figures last refreshed Aug 18, 2026.